Published on
The real-world effectiveness of the respiratory syncytial virus (RSV) vaccination among U.S. adults aged 60 years and older during the 2023–2024 RSV season was found to be 75.1% (95% confidence interval, 73.6–76.4%), according to research published in JAMA Network Open. Vaccine effectiveness was evaluated against acute respiratory infection, urgent care or emergency department visits, and hospitalizations. Among those 60 years and younger, the vaccine was 75.8% effective (73.2-78.1%) against urgent care or emergency department visits specifically; for those aged 60-74 years, it was 76.9% effective (72.9-80.3%); and for those aged 75 years and older it was 76.2% effective (72.9-79.2%).
Be aware: Additionally, adverse event rates for Guillain-Barré syndrome (GBS) and immune thrombocytopenic purpura (ITP) were analyzed among 4.7 million vaccine recipients. While researchers found no increased risk of ITP following RSV vaccination, there was a statistically significant but small increased risk of GBS.